Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors

被引：0
|
作者：
Infante, Jeffrey R.
Gandhi, Leena
Shapiro, Geoffrey
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Hsu, Karl
Faivre, Thea
Asatiani, Ekatherine
Heist, Rebecca Suk
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Sanofi, Cambridge, MA USA
[5] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3118
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
    Infante, Jeffrey R.
    Gandi, Leena
    Shapiro, Geoffrey
    Rizvi, Naiyer
    Burris, Howard A.
    Bendell, Johanna C.
    Baselga, Jose
    Hsu, Karl
    von Richter, Oliver
    Locatelli, Giuseppe
    Asatiani, Ekaterine
    Heist, Rebecca S.
    CANCER RESEARCH, 2013, 73 (08)
  • [2] Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
    Heist, Rebecca Suk
    Gandhi, Leena
    Shapiro, Geoffrey
    Rizvi, Naiyer A.
    Burris, Howard A.
    Bendell, Johanna C.
    Baselga, Jose
    Yerganian, Scott B.
    Hsu, Karl
    Ogden, Janet
    Vincent, Loic
    von Richter, Oliver
    Locatelli, Giuseppe
    Asatiani, Ekatherine
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
    Inaba, Kanako
    Oda, Katsutoshi
    Ikeda, Yuji
    Sone, Kenbun
    Miyasaka, Aid
    Kashiyama, Tomoko
    Fukuda, Tomohiko
    Uehara, Yuriko
    Arimoto, Takahide
    Kuramoto, Hiroyuki
    Wada-Hiraike, Osamu
    Kawana, Kei
    Yano, Tetsu
    Osuga, Yutaka
    Fujii, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 323 - 331
  • [4] Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
    Naing, A.
    Mita, M.
    Komarnitsky, P.
    Milner, A.
    von Richter, O.
    Ogden, J.
    Piha-Paul, S.
    Fu, S.
    Asatiani, E.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 187 - 187
  • [5] Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer
    Sidhu, Sukhvinder S.
    Campana, Frank
    Egile, Coumaran
    Hsu, Karl
    Goodstal, Samantha
    Asatiani, Ekaterine
    Damstrup, Lars
    Lager, Joanne
    Ogden, Janet
    Vincent, Loic
    CLINICAL CANCER RESEARCH, 2013, 19
  • [6] Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Jaenne, Pasi A.
    Cohen, Roger B.
    Laird, A. Douglas
    Mace, Sandrine
    Engelman, Jeffrey A.
    Ruiz-Soto, Rodrigo
    Rockich, Kevin
    Xu, Jianbo
    Shapiro, Geoffrey I.
    Martinez, Pablo
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 316 - 323
  • [7] Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies
    Awan, Farrukh T.
    Gore, Lia
    Gao, Lei
    Sharma, Jyoti
    Lager, Joanne
    Costa, Luciano J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (01) : 55 - 65
  • [8] Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors
    Houede, N.
    Delord, J. P.
    Awada, A.
    Lebbe, C.
    Lesimple, T.
    Schellens, J. H. M.
    Rottey, S.
    Kefford, R.
    von Richter, O.
    Raymond, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 184 - 184
  • [9] Combination of PI3K (SAR245408 and SAR245409) and MEK (MSC1936369B) inhibitors induce tumor apoptosis in vivo: fluorescence molecular tomography study in a human colon carcinoma xenograft model
    Guerif, Stephane
    D'heilly, Sebastien
    Lefranc, Celine
    Egile, Coumaran
    Debusshe, Laurent
    Vincent, Loic
    Carrez, Chantal
    Chiron, Marielle
    Ma, Jiango
    Ogden, Janet A.
    Lager, Joanne
    Garcia-Echeverria, Carlos
    Lengauer, Christoph
    CANCER RESEARCH, 2011, 71
  • [10] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Tabernero, Josep
    Markman, Ben
    Patnaik, Amita
    Tolcher, Anthony W.
    Baselga, Jose
    Shi, Weiliang
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Laird, A. Douglas
    Miles, Dale
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2014, 20 (09) : 2445 - 2456
12345